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             I.INTRODUCTION2-8
                   An ideal dosage regimen in the drug therapy of any disease is the 
one, which immediately attains the desire therapeutics concentration of drug 
in plasma (or at the site of action) and maintains it constant for the entire 
duration  of  treatment.  This  is  possible  through  administration  of 
conventional dosage form in a particular dose and at a particular frequency.1 
Thus drug may be administered by variety of routes in a variety of dosage 
forms.
                   Drugs are more frequently taken by oral administration.  
Although a few drugs taken orally are intended to be dissolved within the 
mouth,  the vast  majority  of drugs taken orally are swallowed.  Compared 
with  alternate  routes,  the  oral  route  of  drug  administration  is  the  most 
popular and has been successfully used for conventional delivery of drug. It 
is  considered  most  natural,  uncomplicated,  convenient,  safe  means  of 
administering  drugs.  Greater  flexibility  in  dosage  form  design,  ease  of 
production and low cost.
                      Drugs are administered by the oral route in a variety of  
pharmaceutical  dosage  forms.  The  most  popular  are  tablets,  capsules, 
suspensions, various pharmaceutical solutions. 2, 3 Among the drugs that are 
administered  orally,  solid  dosage  form  represent  the  preferred  class  of 
product.  They  are  versatile,  flexible  in  dosage  strength,  relatively  stable, 
present lesser problem in formulation and packaging and it is convenient to 
manufactured  store  handle  and  use.  Solid  dosage  form  provides  best 
protection  to  the  drug  against  light,  temperature,  humidity,  oxygen,  and 
stress  during transportation.  Of  the  two oral  dosages  form i.e.  tablets  & 
capsules. Tablets are in wide use.
1.1 TABLETS: 4 
                Tablets may be defined as solid pharmaceutical dosage forms 
containing medicament or medicaments with or without suitable excipients 
& prepared either by compression or moulding.
Advantages of tablets:
• They are the lightest and the most compact of all oral dosage 
form.
• Tablets are easy to packaging and transportation.
• They lend themselves to certain special release profile products 
such as enteric or delayed release products.
• Their cost is lowest of all oral dosage forms.
• Tablets are the unit dose form having greatest capabilities of all 
oral  dosage  form  for  the  dose  precision  and  least  content 
variability.
• Tablets are better suited to large-scale production than other unit 
oral forms.
• They  have  the  best-combined  properties  of  chemical, 
mechanical, microbiological stability of all oral forms.
Disadvantages of tablets:
• Drugs  with  poor  wetting  slow  dissolution  properties, 
intermediate to large dosages, optimum absorption high in the 
GIT, or any combination of these features difficult to formulate.
• Some drugs resist compression in to dense particles, owing to 
their amorphous nature or flocculent, low-density character.
•  Bitter tasting drugs with an objectionable odor, or drugs that are 
sensitive  to  oxygen  or  atmospheric  moisture  may  require 
encapsulation or entrapment prior to compression. 4
1.1.2 Classification of tablets: 5
       Based  on the  route  administration  or  the  function  the  tablets  are 
classified as follows.
1. Tablets ingested orally:
a) Compressed tablets.
b) Multiple compressed tablet.
i. Layered tablet 
ii. Compression  coated tablet
a) Repeat action tablet.
b) Delayed action and enteric coated tablet.
c) Sugar and chocolate coated tablet.
d) Film coated tablet.
e) Chewable tablet.
2. Tablets used in the oral cavity:
a) Buccal tablet.
b) Sublingual tablet.
c) Troches and lozenges.
d) Dental cones.
3. Tablets administered by other routes:
a) Implantation tablet.
b) Vaginal tablets.
4. Tablets used to prepare solution:
a) Effervescent tablet.
b) Dispensing tablet.
c) Hypodermic tablet.
d) Tablets triturate. 
1.2. FORMULATION OF TABLETS: 6,7,8 
1. Diluents:
           Diluents are added where the quantity of active ingredient is small or 
difficult to compress. Common tablet filler include lactose, starch, dibasic 
calcium phosphate  and  microcrystalline  cellulose,  chewable  tablets  often 
contain sucrose, mannital,  sorbitol as a filter, where the amount of active 
ingredients  is  small  the  overall  tableting  properties  are  in  large  measure 
determined  by  the  filler.  Because  of  problems  encountered  with  bio 
availability of hydrophobic drug of low water solubility water soluble are 
used as fillers for these tablets.
2. Binders:
            It  gives  adhesiveness  to  the  powder  during the  preliminary  
granulation  and  to  the  compressed  tablet.  They  added  to  the  cohesive 
strength already available in the diluents while binders may be added dry. 
They  are  more  effective  when  added  out  of  solution,  common  binders 
include  acacia,  gelatin,  sucrose,  povidone,  methyl  cellulose,  CMC, 
hydrolyzed stated pastes. The most effective dry binder is microcrystalline 
cellulose, which is commonly used for this purpose in tablets prepared by 
direct compression.
3. Disintegrating agent:
             It  serves  to  assist  in  the  fragmentation  of  the  tablet  after  
administration. The most widely used tablet disintegration agent is starch, 
chemically  modified  starch  and  cellulose,  aliginic  acid,  microcrystalline 
cellulose  and  cross  linked  povidone,  are  also  used  for  tablet  purposed 
effervescent  mixtures  are  used  in  soluble  tablet  system as  disintegrating 
agents. The concentration of the disintegrating agents, methods of addition 
and degree of compaction play a role of effectiveness. 5 
4. Lubricants:
             They reduce friction during the compression and ejection cycle. In  
addition, they aid in preventing adherence of tablet material to the dies & 
punches.  Metallic stearates,  stearic acid, hydrogenised vegetable oils,  and 
talc  are  used  as  lubricants  because  of  the  nature  of  this  friction,  most 
lubricant  are  hydrophobic  and  such  tend  to  reduce  and  rates  of  tablet 
disintegrator  and  dissolution.  Consequently,  excessive  concentration  of 
lubricant should be avoided. SLS salts have been used as soluble lubricants 
but such agents generally do not posses optimal lubricating properties and 
comparatively high concentrations are usually required.
5. Glidants:
It  is  used  to  improve  powder  fluidity  and  they  are  commonly 
employed in direct compression where no granulation step is involved. The 
most effective glidants are the colloidal pyrogenic silica.
6. Colorants:
           Colorants are often added to tablet formulation for esthetic value or  
for product identification. Most dyes are photosensitive and they fade when
exposed to light. The federal food & drug administration regulates colorants 
employed in drugs.  
7. Flavouring agents:
            These substances are added to impart flavour to lozenges tablets, 
chewable tablets,  etc.  flavouring agents are general nature, therefore they 
must be sprayed over the granulation, compression, e.g. fruit flavours and 
volatile oils.
8. Sweetening agents:
             These substances are added to formulation to improve the and make  
them sweet.  These  agents  are  used  in  lozenges  tablets,  etc.  some  of  the 
common sweetening agents like sucrose and lactose, 5 etc.
1.2.1 Tablet manufacturing methods: 7,8
Tablets  are  manufactured  by  direct  compression  method.  Dry 
granulation and wet granulation method.
1. The direct compression method. 
A compressible  vehicle  is  blended  with  the  medicinal  agent,  and if 
necessary,  with  a  lubricant  and  a  disintegrant,  and  then  the  blend  is 
compressed.  Substances  that  are  commonly  used  as  directly  compressible 
vehicles  are:  anhydrous  lactose,  dicalcium phosphate,  granulated mannitol, 
microcrystalline cellulose, compressible sugar, starch, hydrolyzed starch, and 
a blend of sugar, invert sugar, starch and magnesium stearate. 
2. The dry granulation method (slugging method). 
The ingredients  in the formulation  are  mixed and precompressed on 
heavy duty tablet machines. The slug which is formed is ground to a uniform 
size and compressed into the finished tablet. 
3. The wet granulation method.
This method has more  operational  manipulations,  and is more  time-
consuming than the other methods. The wet granulation method is not suitable 
for drugs which are thermolabile or hydrolyzable by the presence of water in 
the liquid binder.
                    Table no -1.
Processing  steps  commonly  required  in  the  various  tablet 
granulation   preparation technique.
S.No Processing
Step
Wet
Granulation
Dry 
Granulation
Direct 
Compression
1. Raw materials X X X
2. Weight X X X
3. Screen X X X
4. Mix X X
5. Compress (slug) X
6. Wet mass X
7. Mill X
8. Dry X
9. Mill X X
10. Mix X X
11. Compress X X X
COMPRESSION AND COMPACTION:
The  uniaxial  compaction  of  pharmaceutical  powder  results  in  an 
anisotropic and heterogeneous tablet with variations in such properties as 
density, porosity and mechanical strength throughout the tablet . The tablet 
porosity of most materials is about 5 to to 30%. This means that even at 
relatively high compaction pressures, tablets will rarely be non-porous.
1.3. TABLET COATING: 6,7,8
              Tablet coating is done for the fulfillment of the following objective:
Objectives:
    1. Protecting the drug from its surrounding environment with a view to 
improving stability. 
    2. To mask the taste, odor or color of the drug.
    3. To control the release of the drug from the tablet.
    4. To protect the drug from the gastric environment of the stomach with 
an acid resistance enteric coating.
    5. To incorporate  another  drug or  formula  adjuvant  in  the  coating to 
avoid chemical incompatibilities or to provide sequential drug release.
    6. To improve the pharmaceutical elegance by uses of special colors and 
contrasting printing. 7   
Types of tablet coating:
              1. Sugar coating.
              2. Film coating.
1.3.1. Sugar coating:
          Sugar coating is regarded as the oldest method for tablet coating and 
involves  the  deposition  from  aqueous  solution  of  coating  based 
predominantly sucrose as a raw material.
The sugar coating process can be subdivided into six mains steps:
1. Sealing:  
             To prevent moisture penetration into the tablet core, a seal coat is  
applied.
2. Sub coating:
             Is applied to round the edges and build up the tablet size.
3. Smoothing:
             Smoothing usually can be accomplished by the application of 
sample syrup   solution.
4. Color coating:
             Involves the multiple application of syrup solution containing the 
requisite coloring matter.
5. Polishing:
             Is achieved by applying mixtures of waxes to the tablets in a  
polishing pan.
6. Printing:
To identify sugar coated tablets  often it  is  necessary to print  them 
either before or after polishing. 
1.3.2. Film coating:
                Film coating technique reduces process time. Offer greater control 
over coating parameter and provide more opportunity for innovation.
History: 11
                Film coating was introduced in the year of 1950s to combat the 
short comings of the then predominant sugar coating process. Film coating 
has proved successful as a result of the many advantages.
                Film coatings are an integral part of the dosage form development  
process.  The  process  of  film  coating  involves  the  application  of  a  thin 
polymeric film onto the surface of a solid substrate. Though new uses of 
coatings are being continually developed.  The following categories cover 
most current uses. 
Advantages:
• Protection of  drugs  in  the substrate  from environmental  factors 
such as light, moisture, and air, in order to improve chemical and 
physical stability.
• Modification of product appearance to enhance marketability and 
product identify or hide undesirable color changes of the substrate.
• Masking of unpleasant taste, texture or odor.
• Enhancement of swallowability.
• A mechanical barrier to the interaction of incompatible ingredients 
by coating one more of the individual ingredients.
• Improved handling during packaging operations by reducing dust 
formation.
• Controlled or modified release of drugs.
• Increased process efficiency and output.
• Increase flexibility in formation.
• Improved resistance to chipping of the coating. 
Composition of film-coating formulations: 12
             A typical film-coating formulation includes a film-coating polymer, 
insoluble fillers such as pigments and opacifiers,  soluble, insoluble fillers 
add  color  and  protect  from  light.  Pigments  are  usually  aluminum  lakes 
titanium  dioxide.  Soluble  fillers  are  used  to  alter  the  permeability 
characteristics of the film-coating in order to modify taste or control release.
              Film-coating solutions may be nonaqueous or aqueous,  the 
nonaqueous solutions contain the following types of materials to provide the 
desired coating to the tablets.
• A  film  former capable  of  producing  smooth,  thin  films 
reproducible under   conventional coating conditions and applicable to 
variety of tablets shapes.
• An alloying substances providing water solubility or permeability to 
the  film  to  ensure  penetration  by  body  fluids  and  therapeutic 
availability of the drugs.
• A plasticizer to produce flexibility and elasticity of the coating and 
thus provide durability.
• A surfactant to enhance spreadability of the film during application.
• Opaquants  and  colorants to  make  the  appearance  of  the  coated 
tablets handsome and distinctive.
• Sweeteners, flavours, and aromas to enhance the acceptability of the 
tablet to the patient.
• A  glossant to  provide  luster  to  the  tablets  without  a  separates 
polishing operation.
• A volatile solvent to allow the spread of the other components over 
the tablets while allowing rapid evaporation to permits an effective yet 
speedy operation. 
Equipments use in film coating: 13
             1)  Gans-coata system.
             2)   Hi-coater system.
3)   Dry coater system.
4)   Standard coating pan.
5)   Pellegrini pan.
6)   Fluidized bed coater.
7)   Automated coating system. 
2.1    LITERATURE SURVEY. 49,50 
 Bailey r..,(1997)  et.al. Ketorolac  tromethamine  is  a  Non Steroidal  Anti 
Inflammatory  agent.A  prospective,  randomized,  double-blind  study  was 
designed to evaluate the bleeding risk of ketorlac using adult tonsillectomy 
patients as the model. Patients were randomized into two groups receiving 
Meperidine  (MP)  (controls)  or  ketorolac  tromethamine  for  the  first 
postoperative day. Posttonsillectomy bleeding rates of 7% (3/43) in the MP 
group  and  18.9%  (7/37)  in  the  ketorolac  tromethamine  group  were 
demonstrated, but this difference was not statistically significant. This study 
and other reports in the literature support the manufacturer's warning that the 
use  of  ketorolac  tromethamine  is  contraindicated  in  major  surgery. 
Laryngoscope, Page.No. 166-9. 14
Alex Macario.,  (2001)37 et.al., The  recent  introduction  of  oral  COX-2 
selective  NSAIDs  with  potential  for  perioperative  use,  and  the  ongoing 
development of intravenous formulations, stimulated a systemic review of 
efficacy,  side  effects,  and  regulatory  issues  related  to  ketorolac  for 
management of postoperative analgesia.To examine the opioid dose sparing 
effect of ketorolac, we compiled published, randomized controlled trials of 
ketorolac  versus  placebo,  with  opioids  given  for  breakthrough  pain, 
published in English-language journals from 1986–2001. Odds ratios were 
computed to assess whether the use of ketorolac reduced the incidence of 
opioid side effects or improved the quality of analgesia. Ketorolac should be 
administered at the lowest dose necessary. Analgesics that provide effective 
analgesia with minimal adverse effects are needed. Pain Med. Page No. 336-
51. 15
Ohmori shinji., (2004) et.al., The purpose of this study was to develop and 
evaluate  the  thin-layer  sugarless  coated  tablets  containing  Vitamin  C, 
Vitamin E, Vitamin B2, calcium pantothenate, and L-cysteine. As a result of 
the formulation study, three coating layers, 2% Under Coating (UC), 38% 
Build-up Coating  (BC),  and 5% Syrup Coating  (SC)  were  necessary  for 
sufficient  impact  toughness,  elegant  appearance,  and  improvement  of 
appearance stability after storage at 25°C/75% RH for 6 months under open 
conditions. International Journal Pharm. 2004, Page No. 459-69. 16
Fiona  McLeod.,  (2005) et.al., Continuous subcutaneous  infusion  is  a 
method frequently used in palliative care to manage patient symptoms. To 
deliver  the dose required,  and prevent  subcutaneous sites  from becoming 
inflamed and painful, the drug is often diluted in a solution, most commonly 
sterile water for injection or sodium chloride. The use of sterile water for 
injection has been recommended for cyclizine yet beyond this example there 
appears  to  be  limited  clinical  direction  regarding  diluent  selection. 
Inconsistency or lack of guidelines can be problematic if a diluent that may 
enhance the effectiveness of a drug compared with an alternate is not used 
because  of  lack  of  knowledge  or  guidance.National  journal  of  polliative 
nursing. Page No.54-60. 17
M.Cecilia Madamba.,(2007)et.al.,  Laser-Induced  Breakdown 
Spectroscopy  (LIBS)  was evaluated  as  an  early  phase  process  analytical 
technology  (PAT)  tool  for  the  rapid  characterization  of  pharmaceutical 
tablet  coatings.  Model  formulation  tablets  were  coated  with  varying 
amounts (2%-4% w/ws) of red and yellow Opadry II, and a pulsed laser was 
used to sample at multiple sites across the tablet face.  LIBS was able to 
successfully detect the emissions of Fe and Ti in the coated samples, and a 
proportional  increase  in  signal  with  coating  thickness  was 
observed.Increasing photostability was observed with increasing levels of 
ferric  oxide,  providing  a  new  understanding  of  the  photoprotection 
mechanism  in  the  coated  formulation.  Determination  of  levels  of  ferric 
oxide and coating thickness by LIBS demonstrated its utility as a good PAT 
tool for the determination of photoprotection of the drug, thereby enabling 
facile  optimization  of  the  coating  process.AAPS 
PharmSciTech.2007.Article.No.103. 18
Yang  JH.,  (2008)  et.al., This  study  examined  the  effects  of  ketorolac 
tromethamine (KT) and baicalein (BE) on the levels of inflammatory factors 
in human synoviocytes. The fibroblast-like synoviocytes (FLS) cells were 
used to determine the possible regulatory effects of KT and BE (KTBE) on 
the levels of inflammatory factors in FLS cells.  In addition, the levels of 
TNF-alpha, IL-6, and IL-1beta mRNA expression in FLS cells induced by a 
TNF-alpha  and IL-1beta  co-treatment  were  largely  inhibited  by a  KTBE 
treatment.  The level of FLS cells proliferation was increased by IL-1beta 
and TNF-alpha, and strongly inhibited by KTBE treatment. The production 
of  oxygen  species  (ROS)  was  inhibited  by  KTBE  in  FLS  cells.  KTBE 
appears to regulate the levels of mRNA that are important for regulating RA 
progression. Arch Pharm Res. Page No.1517-23. 19
Nagarsenker MS., (2008) et.al., The objective of this investigation was to 
evaluate the effect of delivery strategies such as cyclodextrin complexation 
and  liposomes  on  the  topical  delivery  of  ketorolac  acid  (KTRA)  and 
ketorolac  tromethamine.  Ketorolac  acid-hydroxypropyl-beta-cyclodextrin 
solid dispersions  were prepared by kneading method. The study concluded 
that anti-inflammatory activity of the topically applied KTRA-CD gel was 
similar  to  that  of  the  orally  administered  KTRM.  Thus,  cyclodextrin 
complexation enabled effective transdermal delivery of the ketorolac. AAPS 
PharmSciTech. Page No.1165-70. 20
Moodie JE., (2008) et.al., This study evaluated the safety and efficacy of 
multiple  doses  of  intranasal  ketorolac  tromethamine  (ketorolac)  for 
postoperative pain.    This was a double-blind, placebo-controlled study in 
patients  undergoing  major  surgery  who  were  randomized  to  receive 
intranasal ketorolac, 10 mg or 30 mg, or placebo every 8 h for 40 h. Among 
127 patients enrolled, morphine use during the first 24 h was significantly 
less in patients receiving 30 mg of ketorolac (37.8 mg) than in the placebo 
group (56.5 mg) and in the 10-mg ketorolac group (54.3 mg. Other adverse 
events were reported with similar frequency in all treatment groups and most 
were considered unrelated to treatment. Anesth Analg. Page.No.2025-31. 21
Chelladurai S., (2008) et.al., The present study was aimed at developing 
safe and effective bioadhesive gelling systems of ketorolac tromethamine, a 
potent non-narcotic analgesic with moderate anti-inflammatory activity for 
nasal  systemic  delivery.  The  anti-inflammatory  activity  and  mucosal 
irritancy of selected gels were also evaluated in rats and these results were 
compared with per oral, intraperitoneal and nasal solution administration of 
ketorolac tromethamine. All the prepared formulations gelled immediately at 
the  nasal  mucosal  pH  and  showed  longer  contact  time.  Addition  of 
hydroxypropyl methylcellulose (HPMC) in both chitosan and pectin based 
gelling  systems  increased  the  viscosity  and  gel  strength.  In  vitro  release 
characteristics  were  observed  before  and  after  accelerated  studies.  The 
developed gelling systems produced only mild to negligible irritant effect to 
nasal  mucosae  as  compared  to  control  group. Chem  Pharm  Bull 
(Tokyo).Page No.1596-1599. 22
Hamilton  SM.,  (2008) et.al.,  Myonecrosis  due  to  group  a  streptococci 
(GAS) often  develops  at  sites  of  nonpenetrating muscle  injury,  and Non 
Steroidal Anti-Inflammatory Drugs (NSAIDs) may increase the severity of 
these  cryptic  infections.  We  have  previously  shown  that  GAS  bind  to 
vimentin on injured skeletal muscles in vitro. The present study investigated 
whether vimentin up-regulation in injured muscles in vivo is associated with 
homing of circulating GAS to the injured site and whether NSAIDs facilitate 
this process. J Infect Dis.   Page.No.1692-1698. 23
Genç  L.,  (2008) et.al.,   Controlled  release  matrix  tablets  of  ketorolac 
tromethamine (KT) were prepared by direct  compression technique using 
cellulose  derivatives  as  hydroxypropylmethyl  cellulose  (HPMC), 
hydroxyethyl  cellulose  (HEC),  and  carboxymethyl  cellulose  (CMC)  in 
different  concentrations  (10-20%).  The  effect  of  polymer  type  and 
concentration was investigated on drug release by 2 or 3 factorial designs. 
Dissolution  profiles  of  the  formulations  were  plotted  and  evaluated 
kinetically. An increase in polymer content resulted with a slow release rate 
of  drug  as  was  expected.  According  to  the  dissolution  results,  tablets 
prepared with HPMC + HEC + CMC (F1 and F8) were found to be the most  
suitable formulation for ketorolac. About 99.27% KT was released from F8 
in 7 h.Drug Dev Ind Pharm. Page No.903-910. 24
Alsarra IA., (2008) et.al.,    Ketorolac tromethamine a Non-Steroidal Anti-
Inflammatory Drug, was formulated in buccoadhesive film to overcome the 
limitations  in  the  currently  available  routes  of  administration  which  in 
sequence will increase patients' compliance. The film was formulated using 
aqueous solvents by means of two bioadhesive polymers namely: Hydroxyl 
Propyl Methyl Cellulose (HPMC) and Carbopol 934. The prepared film was 
subjected  to  investigations  for  its  physical  and  mechanical  properties, 
swelling behavior,  in  vitro bioadhesion,  and in  vitro,  in situ  and in  vivo 
release. Results indicate that the concentration of KT in the oral cavity was 
maintained above 4.0 µg/ml for a period of at least 6 h. It is concluded from 
this clinical evaluation that ketorolac formulated into a buccoadhesive film 
is effective as a potent analgesic in dental and postoperative oral surgery in a 
single  dose  of  30  mg  with  minimal  GI  side  effects. Pharmazie  , 
Page.No.773-8. 25
Schechter BA., (2008)  et.al.  Objective this manuscript will review the off-
label application of this topical NSAID medication as a treatment for allergic 
conjunctivitis.  Methods:  An extensive  medline  search  was  undertaken  to 
evaluate data on the use of ketorolac for allergic conjunctivitis. Data on both 
human  and  animal  data  were  reviewed.  Result  of  this  study  have 
demonstrated that ketorolac 0.4% has equivalent efficacy to ketorolac 0.5%. 
Several studies have demonstrated that ketorolac effectively treats allergic 
conjunctivitis. Ketorolac 0.4% is effective when used as either monotherapy 
or as adjunct therapy to steroids. Expert Opin Drug Metab Toxicol. Page 
No.507-11.26
Ohmori S,.,et.al.,  The purpose of this study was to develop and evaluate the 
thin-layer  sugarless  coated  tablets  containing  Vitamin  C,  Vitamin  E, 
Vitamin  B2,  calcium  pantothenate,  and  L-cysteine.  As  a  result  of  the 
formulation  study,  three  coating  layers,  2%  Under  Csoating  (UC),  38% 
Build-up Coating  (BC),  and 5% Syrup Coating  (SC)  were  necessary  for 
sufficient  impact  toughness,  elegant  appearance,  and  improvement  of 
appearance stability  after  storage at  25 degrees C/75% RH for 6 months 
under open conditions. : Int J Pharm., Page.No. 459-69. 27
López-Bojórquez  E (2008) et.al.    Ketorolac  tromethamine  is  a  potent 
nonsteroidal anti-inflammatory drug that is widely used in the treatment of 
moderate to severe pain. A new method was developed and validated for 
quantifying  ketorolac  (the  free  acid  of  the  tromethamine  salt)  in  human 
plasma  by  high-performance  thin-layer  chromatography.  The  stationary 
phase was silica gel 60, and the composition of the mobile phase was n-
butanol-chloroform-acetic acid-ammonium hydroxide-water (9:3:5:1:2, v/v). 
The densitometric analysis of ketorolac was performed at 323 nm. Average 
recovery  was  73.67%.  The  method  proved  to  be  accurate,  precise,  and 
sensitive for the ketorolac tromethamine quantification. J AOAC Int. 2008, 
Page No. 1191-95. 28
Kim  SJ.,  (2008) et.al.   To  evaluate  the  effects  of  topical  ketorolac  in 
patients  undergoing  vitreoretinal  surgery.  One  hundred  nine  patients 
undergoing vitrectomies were randomized to receive either topical ketorolac 
tromethamine, 0.4%, or placebo. Patients were instructed to begin taking the 
study  medication  3  days  preoperatively  (4  times  daily)  and  to  continue 
taking it 4 weeks postoperatively. Arch Ophthalmol. 2008, Page. No. 1203-
1208. 29
Bucci  FA  Jr.,et.al. To  compare  aqueous  drug  concentrations  and 
prostaglandin  E(2)  levels  in  patients  treated  with  ketorolac  0.4%  and 
bromfenac  0.09%  at  trough  dosing.  This  single-center  randomized 
investigator-masked  clinical  study  comprised  56  patients  having  cataract 
surgery. Patients received 1 drop of ketorolac 0.4% or bromfenac 0.09% 6 
hours and 12 hours preoperatively consistent with on-label dosing schedules. 
Aqueous  humor  was  collected  at  the  start  of  surgery  and  analyzed  for 
concentrations  of  ketorolac  and  bromfenac  using  a  reverse-phase  high-
performance  liquid  chromatography-mass  spectroscopy  system  and  for 
prostaglandin  E(2)  levels  by  competitive  enzyme  immunoassay.  These 
findings  suggest  that  ketorolac  0.4%  administered   4  times  a  day  may 
provide  better  control  of  prostaglandin-mediated  inflammation  than 
bromfenac 0.09% administered twice a day. Page.No.1509-1512.30
             
3.1 AIM OF WORK
Ketorolac tromithamine is a member of the pyrrolopyrrole group 
of Non-Steroidal Anti-Inflammatory Drug (NSAID) that exhibits 
analgesic, anti-inflammatory and antipyretic activity. It inhibits the cyclo-
oxygenase enzyme system and hence prostaglandin synthesis. It has more 
pronounced analgesic activity than most NSAIDs. The aim of this work 
was to prepare and evaluate the Ketorolac tromithamine tablets with 
higher dissolution rates. Direct compression method was adopted for 
preparation of tablet using different excipients namely  microcrystalline 
cellulose, spray dried lactose and starch 1500. The effect of excipients on 
the drug release from prepared tablets was also studied. 
• To improve the higher dissolution rate.
• To achieve the short term treatment of the post operative pain 
relief.
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  3.2. PLAN OF WORK
    1.  Preformulation studies.
                     1) IR Spectrum Studies.
                     2) Drug exicipients compatibility studies.
     2.  Formulation of Tablets.
     3.  Evaluation of Tablets.
                     1) Description.
                     2) Identification.
                     3) Uniformity of weight.
                     4) Thickness.
                     5) Hardness.
                     6) Average weight.
                     7) Friability test.
                     8) Rate of disintegration.
                               9) Dissolution.
                             10) Percentage of medicament.
4. Stability studies.
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4.1. RAW MATERIALS USED.
S.No. RAW MATERIALS USED SOURCE
1. Ketorolac tromithamine.
Dr.reddy lab, hyd.
2. Maize starch B.P. Universal starchemallied Ltd.
3. Lactose B.P. Hollandse melkescuti fubricate Ltd.
4. Microcrystalline cellulose Vikash chemicals Pvt.Ltd.
5. Sodium starch glygolate. Vasa pharma chem. Pvt.Ltd
6. Magnesium streate.
Vislak pharma Ltd.
7. Colloidal anhydrous silicon dioxide.
Cabot sanmar Pvt.Ltd.
8. Hydroxy propyl methyl cellulose
Feicheng ruitaitineCo.Ltd.
9. Isopropyl alcohol.
Leechang yung chemicals Ltd
10. Propylene glycol Vislak pharma Ltd.
11. Dichloromethane
Leechang yung chemicals Ltd
12. Titanium dioxide.
Travancore titepam products Ltd.
13. Olive green
Neelicon food dyes,  chemicals.Ltd
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4.2. HANDLING OF EQUIPMENTS
1. Electronical balance.
2. Moisture balance.
3. Mesh different sizes.
4. 16 station rotatatry tablet compression machine.
5. Vernior calipers 
6. Tablet coating pan.
7. Tap density meter.
8. pH meter.
9. Tablet disintegration test machine.
10. Friabilator.
11. Tablet dissolution tester.
12. HPLC chromatogram.
13. Ultraviolet spectrometer.
14. Thermo lab stability chamber.
15.      Fourier Transform Infra Red spectroscopy.
16.      Hot air oven.
17.      Microscope.
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4.3.1. Ketorolac tromithamine31, 32, 37
1. Structure: 
                    
2. Molecular formula:   C15H13NO3·C4H11NO3
3. Molecular weight:   376.40g/mol
4  IUPAC:   1H-Pyrrolizine-1-carboxylic  acid,5-benzoyl-2,3-dihydro,
(±)-,compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1).  
(±)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic  acid,compound 
with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) 
5. Description: ketorolac tromithamine white to off-white to pale yellow 
crystalline powder and free from visible extraneous matter.
6. Solubility:  Freely soluble in water and methanol. Slightly soluble in 
alcohol,  dehydrated  alcohol,  tetrahydrofuran,  toulene,  ethyl  acetate 
and acetonitrile.
7. Pka: 7.9
8. Category: pharmacology stubs, pyrrole pyrrole group of non steroidal 
anti inflammatory drug.
9. Melting point:  255°C
10. Mechanism of actions:
                A highly potent member of a new class of compounds of Non 
Steroidal  Anti-Inflammatory Drug (NSAID) available in Intramuscular 
(IM)  and  oral  formulations  for  the  management  of  acute  pain.  The 
compound  shows  potent  prostaglandin  cyclooxygenase  inhibitory 
activity. The agent elicited mild CNS and cardiovascular activity only at 
doses far in excess of those required for analgesic and anti-inflammatory 
activity.  A  single  10  mg  tablet  given  orally  to  human  volunteers 
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following surgery provided pain relief Equivalent to that provided by 10 
mg of morphine given intramuscularly.
When  administered  intramuscularly  or  orally,  is  a  safe  and 
effective  analgesic  agent  for  the  short-term  management  of  acute 
postoperative pain and can be used as an alternative to opioid therapy
11. Pharmacokinetics:
      1. Absorption:
            Ketorolac is 100% absorbed after oral administration. Oral 
administration of Ketorolac after a high-fat meal resulted in decreased 
peak and delayed time-to-peak concentrations of ketorolac tromethamine 
by about 1 hour. Antacids did not affect the extent of absorption. 
      2. Distribution:
              The mean apparent volume (Vβ) of ketorolac tromethamine 
following  complete  distribution  was  approximately  13  liters.  This 
parameter  was  determined  from  single-dose  data.  The  ketorolac 
tromethamine  racemate  has  been  shown  to  be  highly  protein  bound 
(99%).  Nevertheless,  plasma concentrations as  high as 10 μg/mL will 
only occupy approximately 5% of the albumin binding sites. Thus, the 
unbound  fraction  for  each  enantiomer  will  be  constant  over  the 
therapeutic range. A decrease in serum albumin, however, will result in 
increased free drug concentrations. 
        Ketorolac tromethamine is excreted in human milk.
      3. Metabolism: 
 Ketorolac  tromethamine  is  largely  metabolized  in  the  liver. 
The metabolic products are hydroxylated and conjugated forms of the 
26
parent drug. The products of metabolism, and some unchanged drug, 
are excreted in the urine. 
       4. Elimination:
                      The route of elimination of ketorolac and its metabolites is  
renal. About 92% of a given dose is found in the urine, approximately 
40% as metabolites and 60% as unchanged ketorolac. Approximately 
6% of a dose is excreted in the feces. A single-dose study with 10 mg 
Ketorolac  (n=9)  demonstrated  that  the  S-enantiomer  is  cleared 
approximately  two times faster  than the R-enantiomer  and that  the 
clearance was independent of the route of administration. This means 
that the ratio of S/R plasma concentrations decreases with time after 
each  dose.  There  is  little  or  no  inversion  of  the  R-  to  S-  form in 
humans.  The clearance of  the racemate  in  normal  subjects,  elderly 
individuals  and  in  hepatically  and  renally  impaired  patients  is 
outlined.
12. Therapeutics:
                  Non Steroidal Anti-Inflammatory Drug (NSAID) available in 
intramuscular (IM) and oral formulations for the management of acute 
pain.  The  compound  shows  potent  prostaglandin  cyclooxygenase 
inhibitory  activity  .  The  agent  elicited  mild  CNS  and  cardiovascular 
activity only at doses far in excess of those required for analgesic and 
anti-inflammatory activity. A single 10 mg tablet given orally to human 
volunteers  following  surgery  provided  pain  relief  equivalent  to  that 
provided by 10 mg of morphine given intramuscularly. 37
13. Adverse effects:
               Anorexia,  nausea,  vomiting,  abdominal  pain,  intestinal 
perforation, stomatitis.
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14. Contraindications:
 In children (or) adolescents in the growth phase.
 During pregnancy (or) in breast feeding women.
15. Storage:  Stored in a room temparature
16. Dosage:  10-20mg per daily. 
         4.4.1. MICROCRYSTALLINE CELLULOSE 33
1. Synonym: Avicel PH. Celex, cellulose gel, E 460, celphere, emcocel.
 2. Chemical name:  Cellulose.
3. Empirical formula:     (C6H10O5)n
4. Molecular weight:     ≈  36,000
5. Structural formula:    
                            
6.  Functional  category: Adsorbent,  suspending  agent,  diluent, 
disintegrant,
7.  Description:    White,  odorless,  tasteless,  crystalline  powder 
composed of porous Particles.
8. Typical Properties:
1. Bulk density -- 0.337g/cm3
2. Tapped density – 0.478g/cm3
3. Melting point – 260-270°C
4. Moisture content – less than 5% w/w
   5.     PH         -- 5.0 – 7.0
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9. Solubility:   Slightly soluble in 5% w/v sodium hydroxide solution, 
practically  insoluble in water, dilute acids.
10.  Stability  and storage conditions:  Its  stable  though  hygroscopic 
material. Stored in well-closed container in a cool, dry place.                  
11. Incompatibilities:  It is incompatible with strong oxidizing agents.
12. Safety:  Nontoxic and nonirritant, large quantities of cellulose have a 
laxative   effect. 
                                  
                     4.4.2. SODIUM STARCH GLYCOLATE33 
1. Synonym:  Carboxy methyl starch, sodium salt.
2. Chemical name:   Sodium carboxy methyl starch.
3. Structural formula:
                    
4. Functional category: Disintegrant. 
5.  Description:  White  to  off-white,  odorless,  tasteless,  free  flowing 
powder, oval or spherical granules.
6. Typical Properties:    
1. Bulk density -- 0.756 g/cm
2. Tapped density – 0.945 g/cm
3. True density – 1.443 g/cm
4. Melting point – 200°C
5. Moisture content – less than 10% w/w
6. PH -- 5.5 – 7.5
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7. Solubility: Sparingly soluble in ethanol, practically insoluble in water. 
8. Stability and storage conditions: It’s stable.  Stored in well-closed 
container, protected from light, in a cool, dry place.
9. Incompatibilities: Incompatible with ascorbic acid.
10. Safety:  Nontoxic and nonirritant. 
                               
                            4.4.3. ISOPROPYL ALCOHOL 33
1. Synonym:  Dimethyl carbinol, IPA, isopropanol, 2- propanol
2. Chemical name: Propan –2- ol.
3. Empirical formula:   C3H8O
4. Molecular weight:     60.1
  5. Structural formula:   
                                         
6. Functional category:  Disinfectant, solvent.
7. Description:    Characteristic odour and a warm, bitter taste.             
8. Typical Properties:   
1. Boiling point – 82.4°C
2. Melting point – 88.5°C3. 
3. Moisture content – 0.1 – 13 % w/w.
9. Solubility: Clear, colorless, volatile, flammable liquid, slightly bitter 
taste.                 
10. Stability and storage conditions: Stored in well-closed container, 
protected from light, in a cool, dry place.
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11. Incompatibilities:  Incompatible  with  oxidizing  agents  such  as 
hydrogen peroxide, nitric acid, which cause decomposition.
12. Safety:  Nontoxic and local irritant. 
                         
 4.4.4. MAGNESIUM STEARATE 33, 34 
1. Synonym: Octadecanoic acid, magnesium salt, stearic acid.
2. Chemical name: Octadecanoic acid magnesium salt.
3. Empirical formula:  C36H70MgO4.
4. Molecular weight:     591.34
5. Structural formula:  (CH3 (CH2)16COO) Mg.
6. Functional category:  Lubricant. 
7. Description: Fine, white, precipitated, faint odour, characteristic taste. 
8. Typical Properties:
1. Bulk density -- 0.159 g/cm
2. Tapped density – 0.286 g/cm
3. True density – 1.092 g/cm
4. Melting point – 126 to 130°C 
9. Solubility:  Soluble in ethanol, water, insoluble in miner oil, vegetable 
oil.                  
10. Stability and storage conditions:  It’s stable. Stored in well-closed 
container, protected from light, in a cool, dry place.                
11. Incompatibilities: Incompatible with strong acids, alkalis, iron salts, 
avoid mixing with strong oxidizing materials.
12. Safety: Nontoxic and mucosal irritant. 
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                     4.4.5. COLLOIDAL SILICON DIOXIDE 34, 36
1. Synonym: Aerosil, cab-o-sil, colloidal silica, fumed silica.
2. Chemical name: Silica
3. Empirical formula:     SIO2
4. Molecular weight:    60.08
5.  Functional  category:  Adsorbent,  emulsifying  agent,  suspending 
agent, Anticaking agent, glidant, disintegrant.
6. Description: Light, loose, bluish-white colored, odourless, tasteless, 
7. Typical Properties:
1. Bulk density -- 0.29 to 0.042 g/cm
2. Tapped density – 0.04 to 0.05 g/cm
 3. PH -- 3.4 – 4.4
8.  Solubility: Practically  insoluble  in  organic  solvents,  water,  acids, 
soluble in hot solutions of alkali hydroxide.
9. Stability and storage conditions:  It’s hygroscopic but absorbs large 
quantities of   water without liquefying. Stored in well-closed container, 
protected  from light, in a cool, dry place.
10. Incompatibilities:  Incompatible with diethylstilbestrol preparations.
11. Safety:  Nontoxic and nonirritant.   
                                 
       4.4.6. HYDROXY PROPYLMETHYL CELLULOSE 35, 36 
1. Synonym: Cellulose, E464, HPMC, methocel.
2. Chemical name: Cellulose, 2-hydroxy propyl methyl ether.
3. Empirical formula: (OCH2CH (OH) CH3)
4. Molecular weight:  1, 00, 00 to 1, 50, 00
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5.Structuralformula: 
6. Functional category:  Coating agent, film former, stabilizing agent, 
suspending agent, binding agent.
7. Description:  Odorless, tasteless, white or creamy white fibrous. 
8. Typical Properties:
       1.  Bulk density -- 0.341 g/cm
2.  Tapped density – 0.557 g/cm
3.  True density – 1.326 g/cm
4.  Melting point – 190 to 200°C 
 5. PH -- 5.5 – 8.0
9.  Solubility: Soluble  in  cold  water,  practically  insoluble  in  ethanol, 
ether.                        
10.  Stability  and  storage  conditions: Its  stable  material,  it’s 
hygroscopic after drying. Stored in well-closed container, protected from 
light, in a cool, dry place.
11. Incompatibilities: Incompatible with some oxidizing agents.
12. Safety:  Nontoxic and nonirritant.
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                                          4.4.7. TITANIUM DIOXIDE 36
1. Synonym: Titanic anhydride, tronox, tioxide, tipure.
2. Chemical name: Titanius oxide.
3. Empirical formula: TIO2
4. Molecular weight: 79.88
5. Functional category: Coating agent, opacifier, and pigment.
6. Description:  White,  amorphous,  odorless,  tasteless,  nonhygroscopic 
powder.       
 7. Typical Properties:
       1. Bulk density -- 0.4 to 0.62 g/cm
2. Tapped density – 0.625 to 0.830 g/cm
3. True density – 3.8 to 4.1 g/cm
4. Melting point – 1855°C 
8. Solubility: Practically insoluble in dilute sulphuric acid, nitric acid. 
9.  Stability  and  storage  conditions: It’s  extremely  stable  at  high 
temperatures, stored in well-closed container, protected from light, in a 
cool, Dry place.
10. Incompatibilities: Incompatible with certain active substances, and 
also unsaturated lipids.
11. Safety:  Nontoxic and nonirritant.     
                           4.4.8. LACTOSE35, 36 
 1.  Synonym:  Fast-Flo;  4-(b-D-galactosido)-D-glucose;  Lactochem; 
Microtose;  milk  sugar;  Pharmatose;  saccharum  lactis;  Tablettose; 
Zeparox.
2. Chemical name: 
        D-Galactopyranosyl-(1,4)-D-glucopyranose anhydrous.
        D-Galactopyranosyl-(1, 4)-D-glucopyranose monohydrate.
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3. Empirical formula:  C12H22O11
4. Molecular weight: 342.30
5. Functional category: Tablet and capsule diluent.
6.  Description:  White  to  off-white  crystalline  particles  or  powder. 
Lactose is odorless and slightly sweet-tasting; a-lactose is approximately 
15% as sweet as sucrose, while b-lactose is sweeter than the a-form of 
lactose.
7. Typical Properties:
       1. Bulk density -- 1.589 for anhydrous b-lactose
          2. Melting point - 223°C for anhydrous a-lactose; 
                                       252.2°C for anhydrous b-lactose
8. Solubility: Practically insoluble in dilute sulphuric acid, nitric acid. 
9.  Stability  and  storage  conditions: chlorafrom,  ethanol,  ether  and 
water.
10.  Incompatibilities: Lactose  is  incompatible  with  amino  acids, 
aminophylline, and amphetamines.
11. Safety:  Nontoxic and nonirritant. 
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4.4.9. MAIZE STARCH36 
1. Synonym: Bio-sorb; double-dressed, white maize starch; Keoflo ADP, 
Fluidamid  R444P;  modified  starch  dusting  powder;  Pure-Dent  B851; 
starch-derivative dusting powder; sterilizable corn starch
2. Chemical name: Sterilizable maize starch
3. Empirical formula: (C6H10O5) n
 4. Molecular weight: Where n = 300-1000.
Sterilizable  maize  starch  is  a  modified  corn  (maize)  starch  that 
may also contain up to 2.0% of magnesium oxide.
5.  Functional  category: Lubricant  for  surgeons’  and  examination 
gloves; vehicle for medicated dusting powders.
 6. Description:  Sterilizable maize starch occurs as an odorless, white-
colored, free-flowing powder. Particles may be rounded or polyhedral in 
shape.
7. Typical Properties:
       pH = 9.5-10.8 for a 10% w/v suspension at 25°C.
Density: 1.48 g/cm3
Density (bulk): 0.47-0.59 g/cm3
Density (tapped): 0.64-0.83 g/cm3
Flowability: 24-30% (Carr compressibility index)
Moisture content: 10-15%
Particle size distribution: 6-25 µm; median diameter is 16 µm.
9.  Solubility: very  slightly  soluble  in  chloroform and  ethanol  (95%); 
practically insoluble in water.                
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10. Stability and storage conditions:  Sterilizable maize starch may be 
sterilized by autoclaving at 121°C for 20 minutes, by ethylene oxide or 
by irradiation.Sterilizable maize starch should be stored in a well-closed 
container in a cool, dry, place.
11. Safety:  Nontoxic and nonirritant. 
            4.4.10. PROPYLENE GLYCOL36
1.  Synonym:     1,  2-Dihydroxypropane;  2-hydroxypropanol;  methyl 
ethylene glycol; methyl glycol; propane-1,2-diol.
2. Chemical name: 
                 1,2-Propanediol 
 
3. Empirical formula:  C3H8O2 
4. Molecular weight: 76.1
5.  Functional  category: Antimicrobial  preservative,  disinfectant, 
humectant,  plasticizer,  solvent,  stabilizer  for  vitamins,  water-miscible 
cosolvent.
6. Description: Propylene glycol is a clear, colorless, viscous, practically 
odorless liquid with a sweet, slightly acrid taste resembling glycerin.
7. Typical Properties:
       Density: 1.038 g/cm3 at 20°C
Flammability:  upper  limit,  12.6%  v/v  in  air;  lower  limit, 
2.6% v/v in air.
Flash point: 99°C (open cup)
Heat of combustion: 1803.3 kJ/mol (431.0 kcal/mol)
Heat of vaporization: 705.4 J/g (168.6 cal/g) at b.p.
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Melting point: 59°C
8. Solubility: Practically insoluble in dilute sulphuric acid, nitric acid. 
9.  Stability  and  storage  conditions: chlorafrom,  ethanol,  ether  and 
water.
10.  Incompatibilities: Lactose  is  incompatible  with  amino  acids, 
aminophylline and amphetamines.
11. Safety:  Nontoxic and nonirritant. 
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4.5.1 PREFORMULATION STUDY
             Preformulation testing is an investigation of physical properties 
of a drug substances alone and when combined with excipients. It is the 
first step in the rational development of dosage forms.
4.5.2. Identification of drug:
             The identification of drug was done by IR spectroscopy. The 
FTIR spectrum of pure drug ketorolac is shown in 
Figure no: 1
Method:  
Triturate 1-2 mg of the substance to be examined with 300-400 
mg, unless otherwise specified, of finely powdered and dried potassium 
bromide  R  or  pottasium  chloride  R.   These  quantities  are  usually 
sufficient to give a disc of 10-15 mm diameter and a spectrum of suitable 
intensity.  Infrared spectrophotometers are used for recording spectra in 
the region of 4000 – 650 cm-1.
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       FTIR Spectrum of ketorolac.
                    
      
Figure No.1
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5.4. Drugs – Excipients compatibility study: 39, 40 
                Drug was mixed with excipients in difficult ratio. These  
mixtures were kept in a 2 ml glass vial and exposed to 40ºC, 60ºC, for 1 
month. At the end of 30 days. 
                            Table no. 2. ketorolac + Excipients Compatibility Studies.
S.No            Ingredients Initial colour
         Storage Conditions
40°C/75% RH 60°C/80% RH
At the end of 30 daysAt the end of 30 days
1.
Drug (D). PW PW PW
2.
D+ Lactose. W W W
3.
D+Microcrystalline cellulose.
W W W
4. D+Maize starch.
W
W W
5. D+Sodium starch glycolate. W W W
6. HPMC W W W
7. D+propylene glycol. W W W
8.
D+Isopropyl alcohol. W W W
9. D+Magnesium stearate. W W W
10. D+Colloidal silicon dioxide. W W W
11.
D+Talc. W W W
12.
D+Olive green. O O O
                                  W- white:  PY- pale yellow:  PW- pale white:  O- orange: 
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Table .no.3.
        Physical characteristics of ketorolac tromithamine.
S.No Parameter
Observation
    ketorolac
    1.  Loss on drying.    Less than 0.07%
     2.  Bulk density.    0.471 --  0.478 g/cc
    3.  Tapped density.    0.661 -- 0.668 g/cc
    4.  Compressibility index.    28.74 -- 29.52%
    5.  Hausner ratio.    1.403 -- 1.408
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  4.6.1. FORMULATION OF TABLET39-43
The  key  process  in  the  formulation  development  of  ketorolac 
tromithamine tablets including direct compression method to be adopted 
using  different  excipients  and  before  weighing  active  ingredient.  The 
dispensing area maintained temperature below 25ºC and humidity below 
30 % RH.
Dry  Blending  and  Preparation  of  Tablets  by  Direct  Compression 
Technique: 
All  of  the  mentioned  materials  except  lubricant  and  glidant  of 
respective  formulation  were taken into a  bowl by passing through 40 
mesh screen (if necessary) and mixed manually for five minutes. Then 
this mixture was mixed in a tumbling mixer Patterson-kelly Twin shell 
blender for about fifteen minutes. The effiency of mixing was verified by 
determination  of  drug  content.  Magnesium  stearate,  colloidal  silicon 
dioxide
I. PREMIXING:
1. Drugs+diluent+disintegration+lubricant.  All  the  products 
through 40 mesh, for 30 minutes.
                                      
2. Binding agents.
                 
                                             
3. 1  and  2  step-1  material  and  mix  well  till  uniformity  is 
obtained.
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II. LUBRICATION:
1. Charged the blender with material
2. Sifted  drug+glidant+disintegrant.  Through  30  mesh  in  a 
mechanical sifter.
                                   
3. Added above sieved materials to the blender and mixed for 
15 minutes.
4. Sieved lubricant through 40 mesh.
5. Added to the blended materials and mixed for 5 minutes.
6. Stored  the  lubricated  material  in  a  airtight  container  and 
keep in a cool place at temperature between 25°C to 30°C.
7. Compression  carried  out  only  after  getting  in  process 
approval for material from quality control department.
                                     
8. Set  the  16  station  rotary  compression  machine  using 
punches and dies.
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9. Compression  carried  out  only  with  air  conditioned  and 
dehumidified  atmosphere.  Maintained the temperature and 
relative humidity of compression section at not more then 
32°C and 65% respectively.
10.Loaded  material  into  the  hopper  of  rotary  compression 
machine and adjusted the machine for compression weight, 
hardness, thickness, disintegration time and friability as per 
the specification on parameters in IP. 
Table. No.4, Design and development of formulation.
4.6.2. Preparation of coating solutions
                                                  Table.no.5.
S.No Ingredients mg/tablet
1. HPMC 2 mg
2. Isopropyl alcohol 0.25 ml
3. Propylene glycol 0.5 mg
4. Dichloro methane 2 mg
5. Olive Green 0.90mg
Procedure:
Pass all  the materials  from the sieve no 200# and then mix the 
Dichloromethane and propylene glycol, in a coating solution tank. Then 
add  HPMC  with  isopropyl  alcohol  in  small  quantity  while  stirring 
continuously till it forms a smooth suspension. 
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Add the olive green with the remaining quantity of the isopropyl 
alcohol.  Mill  the  above  preparation  dispersion  in  colloidal  mill  with 
recirculation for 5min. transfer to the agitator tank while filtering through 
200# nylon cloth.
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4.7. IN PROCESS EVALUATION39,40
 4.7.1. Determination of bulk density: 
                    An accurately weighed quantity of the powder (W) was 
carefully poured into the graduated cylinder and the volume (V0) was 
measured. Then the graduated cylinder was closed with lid. Set into the 
density  determination  apparatus  (bulk  density  apparatus.  Electro  lab, 
Mumbai.)
The bulk densities were calculated using the  following formula:
Bulk density = W/V0
Where,
          W = Weight of powder. 
         V0 = Initial volume.
          The results are presented in the table no:  6  
4.7.2. Determination of tapped density: 
                      An accurately weighed quantity of the powder (W) was 
carefully poured into the graduated cylinder and the volume (V0) was 
measured. Then the graduated cylinder was closed with lid. The density 
apparatus (tapped density apparatus. Electro lab, Mumbai.). Was set 100 
taps  and  after  that,  the  volume  (Vf)  was  measured  and  continued 
operation till the two consecutive readings were equal. 
 The tapped densities were calculated using the following formula:  
                        Tapped density = W/Vf
Where,
W = Weight of powder. 
         Vf = Final volume.
          The results are presented in the table no:  6 
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4.7.3. Compressibility index: 43
            Compressibility index is an important  measure that can be 
obtained  from  the  bulk  and  tapped  densities.  In  theory,  the  less 
compressible a material the more flowable it is. A material having values 
of less than 20 to 30 % is defined as the free flowing material. 
 The compressibility indexes were calculated using the following 
formula:  
                                         100 (V0 – Vf)
                          C1   =    --------------------- 
                                                 V0 
The results are presented in the table no: 9
4.7.4. Hausner ratio: 43
               Hausner ratio is an important measure that can be obtained from 
the bulk and tapped densities. In theory, the less compressible a material 
the more flowable. 
 The hausner ratios were calculated using the following formula:  
                        
                        Tapped density
              Hausner ratio   =    --------------------
                                                 Bulk density
The results are presented in the table no: 6
48
4.7.5. Loss on drying: 43 
             Determinations of loss on drying of material are important.  
Drying time during material was optimized depending on the LOD value. 
LOD of each batches were tested at 63ºC and 105ºC temperature by using 
“Moisture balance” electronic LOD apparatus. 
% LOD = [lost wt X 100]/wt of sample
 The results are presented in the table no: 6
4.7.6. Sieve analysis: 40, 43 
              The main aim of sieve analysis is to determine the difficult size  
of drug particles present. A series of standard sieves were stacked one 
above the other so that sieves with larger pore size (less sieve number) 
occupy top position followed by sieves of decreasing pore size (large 
sieve number) towards the bottom. 
Procedure:
               A series of sieves were arranged in the order of their decreasing 
pore diameter. (increasing in sieve number) i.e. sieve number #20, #40, 
#60, #80, and #100 passed. 100 gms of drugs were weighed accurately 
and transferred to sieve #20, which was kept on top. The sieves were 
shaken for  about  5-10 minutes.  Then the drug retained on each sieve 
were taken,  weighed separately and expressed in terms of percentage. 
The results are presented in the table no: 7
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Table. No.6.
Physical characteristics of blend material (formulation 1-9)
S.No Formulation 
No
% Loss on 
drying
Bulk
density (g/cc)
Tapped
 density (g/cc)
Compressibility
index (%)
Hausner
ratio
1. F-1 2.420 0.5241 0.6823 23.16 1.304
2. F-2 2.287 0.5678 0.6834 25.76 1.347
3. F-3 2.346 0.5352 0.7191 25.59 1.343
4. F-4 2.336 0.5704 0.7540 24.40 1.322
5. F-5 2.289 0.5502 0.7319 24.76 1.329
6. F-6 2.341 0.5843 0.7624 23.35 1.304
7. F-7 2.287 0.5432 0.7465 24.89 1.327
8. F-8 2.298 0.5673 0.6834 23.15 1.342
9. F-9 2.316 0.5732 0.673 25.13 1.302
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Table.no.7.
Sieve Analysis of blend material,Formulation: (1 – 9)
S.No. Seive.No.                                % weight of blend material retained
F-1 F-2 F-3 F-4 F-5 F-6 F-7 F-8 F-9
1. # 20 8.00 6.00 6.00 0.00 2.00 0.00 0.00 0.00 0.00
2. # 30 3.13 2.03 0.19 0.00 0.15 21.02 37.67 49.35
19.02
3. # 40 39.72 40.82 10.19 13.73 23.77 22.00 17.15 20.00
21.15
4 # 60 17.52 14.25 18.62 11.72 14.05 8.41 10.63 17.25 7.32
5 # 100 4.62 3.65 8.54 1.25 10.32 6.58 4.61 4.56
7.51
6 ># 100 29.21 30.20 64.25 58.20 56.80 12.56 14.64 11.24
13.02
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6.1. DISSOLUTION42,44
                      Tablet dissolution was assessed using standard USP 24  
apparatus  II  in  900  ml  of  water.  The  stirring  speed  was  50  rpm. 
(Revolution per minutes). Total 6 tablets were taken for test. Temperature 
was maintained 37ºC ± 0.5ºC through out the experiment.  Dissolution 
study was carried out for 45 minutes. Sampling interval were 5 min, 10 
min, 15min, 20 min, 30 min. After collection of sample in each interval, 
dissolution medium was replenished with the same volume of respective 
medium. Samples were withdrawn at regular intervals and diluted to 25 
ml with corresponding medium and analyzed for drug content by U.V. 61
Dissolution parameters:
1. Medium                :   purified water (degassed).
2. Quantity                :   900 ml.
3. Apparatus              :   USP Type II (paddle).
4. Rotational Speed   :    50 rpm
5. Time                      :    5, 10, 15, 20, 30min or required intervals.
6. Temperature          :    37ºC ± 0.5ºC.
7. Wavelength     :    322nm.
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Standard solution Preparation:
                Weigh accurately about 42mg working standard into a 
100ml volumetric flask. Dissolve and dilute to volume with water and 
mix. Transfer 2ml of this solution to a200 ml volumetric flask and dilute 
to volume with water and mix.
Preparation of sample solution:
                Put 6 tablets in the six dissolution flask containing 900ml of 
water  that  has  been  equilibrated  to  37ºC ±  0.5ºC.  Start  the  apparatus 
immediately. Collect the sample after 45min. withdraw the sample from 
the zone mid way between the surface of  the medium and top of the 
rotating  blade  and  not  less  than  1cm from the  vessel  wall  and  filter 
through  0.45  micron  membrane  filter  and  discard  the  first  5  ml  and 
transfer 5ml of filtrate into a 20ml volumetric flask and dilute to volume 
with water and mix.
Procedure:
Check  the  absorbance  of  both  standard  and  the  sample 
preparation using U.V spectroscopy at 322nm using water as blank.
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Calculations:  (for Ketorolac tromethamine):
                  
         % W/W of Assay =
                                ATA          SW           2         600          20            
                               ---------- X -------- X ------ X -------- X -------- X P 
ASA            100         200         LC            5          
Where,
       ATA =   Average peak area counts for test solution.
       ASA =   Average peak area counts for standard solution.
       SW =     Weight of standard solution taken. In mg
       P =      Purity of working standard. In mg
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                    Table.no.11. Dissolution Profile of Formulation – 1 
S.no Time in minutes cumulative % drug 
release
1 00 0
2 5 12.20
3 10 27.30
4 15 42.30
5 20 68.42
6 30 76.52
                                              Figure no- 2.
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                    Table.no.12. Dissolution Profile of Formulation – 2
S.no Time in minutes cumulative % drug 
release
1 00 0
2 5 23.22
3 10 36.82
4 15 56.62
5 20 72.30
6 30 79.12
      Figure no- 3.
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                  Table.no.13. Dissolution Profile of Formulation – 3
S.no Time in minutes cumulative % drug 
release
1 00 0
2 5 24.71
3 10 37.19
4 15 60.12
5 20 76.27
6 30 82.48
                Figure no- 4.
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                Table.no.14. Dissolution Profile of Formulation – 4 
S.no Time in minutes cumulative % drug 
release
1 00 0
2 5 24.35
3 10 39.40
4 15 63.83
5 20 78.25
6 30 89.40
Figure no- 5.
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     Table.no.15. Dissolution Profile of Formulation – 5 
S.no Time in minutes cumulative % drug 
release
1 00 0
2 5 23.45
3 10 40.63
4 15 64.10
5 20 82.18
6 30 91.20
                            Figure no- 6.
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                Table.no.16. Dissolution Profile of Formulation – 6 
S.no Time in minutes cumulative % drug 
release
1 00 0
2 5 24.72
3 10 38.92
4 15 63.73
5 20 85.10
6 30 94.52
                Figure no- 7.
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Table.no.17. Dissolution Profile of Formulation – 7
S.no Time in minutes cumulative % drug 
release
1 00 0
2 5 26.40
3 10 41.50
4 15 64.12
5 20 84.34
6 30 93.26
         
       Figure no- 8.
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Table.no.18. Dissolution Profile of Formulation – 8
S.no Time in minutes cumulative % drug 
release
1 00 0
2 5 27.62
3 10 48.32
4 15 68.43
5 20 82.84
6 30 99.62
                 Figure no-9
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Table.no.19. Dissolution Profile of Formulation – 9
S.no Time in minutes cumulative % drug 
release
1 00 0
2 5 23.12
3 10 36.72
4 15 62.14
5 20 87.26
6 30 98.47
            
     Figure no-10
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Table. No-20.
 Dissolution Profile of Ketorolac tromethamine in (F1-F9).
S.No. Time 
(min)
                               cumulative % drug release
F-1 F-2 F-3 F-4 F-5 F-6 F-7 F-8 F-9
1. 0 0 0 0 0 0 0 0 0 0
2. 5 12.2
0
23.2
2
24.7
1
24.3
5
23.4
5
24.7
2
26.4
0
27.6
2
23.12
3. 10 27.3
0
36.8
2
37.1
9
39.4
0
40.6
3
38.9
2
41.5
0
48.3
2
36.72
4 15 42.3
0
56.6
2
60.1
2
63.8
3
64.1
0
63.7
3
64.1
2
68.4
3
62.14
5 20 68.4
2
72.3
0
76.2
7
78.2
5
82.1
8
85.1
0
84.3
4
82.8
4
87.26
6 30 76.5
2
79.1
2
82.4
8
89.4
0
91.2
0
94.5
2
93.2
6
99.6
2
98.47
                                                   Figure no-11.
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           Table.no.21. Dissolution Profile of Marketed Product:
S.no Time in minutes cumulative % drug 
release
1 00 0
2 5 26.31
3 10 43.27
4 15 64.51
5 20 82.36
6 30 96.52
                                                 
  Figure no- 12.
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  5.1. EVALUATION OF TABLETS42,43
5.1. THICKNESS OF TABLET: 43
                    The thickness of the tablets was measured by using Digital 
Vernier Caliper thickness tester in mm. twenty tablets from each batch 
were randomly selected and thickness were measured. The thickness of 
IP limits is 3.40 ±0.2mm.
 The mean of measured thickness of tablets of each batch are shown in 
table no: 9
5.2. HARDNESS OF TABLET: 43 
                      Hardness of the tablets was determined by using Digital 
Hardness Tester. Twenty tablets from each batch were randomly 
selected. The force required to break the tablet is recorded. The unit is 
Newton. The hardness of IP limits is NLT 5-8 kg/cm2. 
 The mean of measured hardness of tablets of each batch are shown in 
table no: 9
5.3. FRIABILITY OF TABLET: 43
                       Friability of the tablets was tested using a Friabilator 
(Friability testing apparatus, Electro lab). A loss of less than 1& in 
weight was acceptable. The weight of 10 tablets was noted initially (W1) 
and placed in the friabilitor for 4 minutes/25 rpm. (Revolution per 
minutes).The tablets were reweighed and noted as (W2). 
 The difference in the weight is noted and expressed as percentage.
                                                                      (W1 – W2) 100
                 Percentage friability (%F) =      ------------------------ 
                                                                               W1        
Where,
          %F = Friability in percentage.
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          W1 = Initial weight of tablet.
           W2 = Weight of tablets after revolution.          
      The mean of measured friability of tablets of each batch are shown in 
table no: 9
5.4. WEIGHT VARIATION TEST: 42 
                   Twenty tablets were randomly selected from each batch and 
individually weighed. The average weight and standard deviation of 20 
tablets was calculated. The batch passes the test for weight variation test 
if not more than two of the individual tablet weight deviates from the 
average weight by more than the percentage shown in table, and none 
deviate by more than twice the percentage shown. 
Table. no - 8.
Weight variation tolerance for tablet (USP)
5.5. DISINTEGRATION OF TABLET: 
Method:
           The tablets were taken in a rigid basket rack assembly supporting 
six cylindrical glass tubes. The glass tubes are of 77.5 ± 2.5 mm long. 
21.5 mm in internal diameters and with a wall thickness of about 2mm. 
the assembly was suspended in the liquid medium in a 1000 ml beaker. 
The volume of liquid was such that, wire mesh at its lower point was at 
25 mm below the surface of the liquid and its lower point was at 25 mm 
above the bottom of the beaker. A temperature was maintained at 37º± 2º. 
Five tablets are placed in each tube and the motor is switched on. Guided 
disc over the tablets does not allow them to float and imparts a slight 
pressure on the tablets. The tubes are then allowed 30 up and down 
movements till all the tablets disintegrate and particles remain above the 
wire mesh. Finally the average disintegration time was recorded. The 
disintegration of USP limits is NMT 10minutes. 
Observation: the value of the disintegration time of all the batches given 
in the table no: 9
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Table.no.9. Pysical Characteristic of Finished products.
 5.6. AVERAGE DRUG CONTENT 
5.6.1. Assay (By HPLC): 42
Reagents:
1. Hydrochloric acid.
2. Sodium lauryl sulphate: HPLC grade.
3. Acetonitrile: HPLC grade.
4. Glacial acetic acid: HPLC grade.
5. HPLC grade water: Millie Q or equivalent.
Preparation of mono basic ammonium phosphate Buffer Solution:
                  Dissolve the 5.75g ammonium phosphate in 1000ml of HPLC  
grade water in suitable container; dissolve it  and then make up to the 
volume with water and adjust the pH of 3.0. 
Preparation of mobile phase:
                Prepare  a  filtered  and degassed  mixer  of  buffer  and 
tertrahydrofuran in the ratio of 70:30 v/v.
Note:  make  adjustment  if  necessary  to  achieve  a  retention  time  for 
ketorolac of about 8-12 min. 
Blank: use mobile phase as blank.
Chromatographic parameters:
      Use suitable high performance liquid chromatograph equipped with 
following:
1. Column                         :  4.6mm X 25cm
2. Column temperature     :    40ºC
3. Sample compartment    :    10ºC
4. Flow rate                       :    1.5 ml/mins
5. Wavelength                   :    313 nm
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6. Injection volume           :    10 µl
7. Run time                        :    about 15 minutes.
8.   Diluent                          :     HPLC grade water.
Preparation of standard stock for ketorolac:
                 Weigh and transfer accurately about 40 mg of ketorolac in to  
100 ml of volumetric flask. And dissolve and dilute with to volume with 
solvent mixture and mix. Sonicate (use ice chilled water in the sonicator 
to avoid heating of sample) 
 Test preparation:
                 Weigh and crush not less than 20 tablets. Weigh and transfer  
equivalent to one tablet into 50 ml volumetric flask, dissolve and dilute to 
volume with solvent mixture.
Procedure:
      Separately inject equal volume of blank. Standard preparation and 
test  preparation  in  to  the  chromatograph  and  measure  the  peak  area 
counts for ketorolac tromithamine. 
Evaluation of system suitability:
1. The RSD for the peak area counts of ketorolac tromithamine from 4 
injections of standard solution should not be more than 2.0 %
2. The tailing factor for ketorolac tromithamine should not be more 
than 2.0. 
Calculations:  (for ketorolac tromithamine):       
           
                                          ATA          TW        50       PS             
     % W/W of Assay =    -------- X -------- X ------ X ------- X AW X 1000 
                                         A              50           SW       100
83
Where,
      ATA =   Average peak area counts for test solution.
      ASA =   Average peak area counts for standard solution.
      TW   =   Weight of test solution taken. In mg
      SW =     Weight of standard solution taken. In mg
      PS  =      Purity of working standard. In mg
     AW =     Average weight of tablet. In mg.
 Table.no.10. Average Drug Content. 
S.No. Formulation 
no
Cumulative % 
drug Release
1. F-1 80.32
2. F-2 82.21
3. F-3 93.20
4. F-4 94.51
5. F-5 97.60
6. F-6 98.93
7. F-7 98.20
8. F-8 99.62
9. F-9 98.93
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8.1. RESULTS AND DISSCUSSION
8.1.1. Preformulation studies:
The  procured  sample  of  ketorolac  tromethamine  was  tested  by 
Dr.Reddy’s laboratories.  The manufactured also confirmed quality and 
purity of sample.
The drug-excipients compatibility  was done at  40ºC/ 75 % RH. 
60ºC/ 80 % RH. Open and closed vial methods were used. The result did 
not show any physical change to the mixture after interval at the end of 
30 days. This fact concluded that the drug and excipients are compatible 
with each other.
8.1.2. Physiochemical parameters and drug release pattern:
                 The tablets of ketorolac tromethamine were prepared by direct  
compression  and  were  evaluated  for  weight  variation,  drug  content, 
friability,  hardness,  thickness  and  drug  release  pattern  for  all  the 
formulation 1 to 9.
                  Deals with results of all formulations 1 to 9 and experiments  
and their discussions.
Formulation - 1:
Hardness, weight variation, defective in dies and punches occurs 
due to excessive fine powder were observed during compression. So, in 
the  next  batch,  add  with  sodium  starch  glycolate  and  decreases  the 
concentration of the maize starch.
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Formulation - 2:
There was a flow problem and capping problems occurs. So, in the 
next batch add sodium starch glycolate and increased quantity.
Formulation - 3:
Colloidal  silicon dioxide produced black dots  in the tablets  and 
excessive increasing in the disintegration time. So, in the next batch we 
decreases the concentration of maize starch and colloidal silicon dioxide 
Formulation - 4:
Due  to  excessive  fines  the  formulation  is  occurs  capping  and 
insufficient lubricant picking and sticking occurs. So in the next batch 
increase the concentration of maize starch.
Formulation - 5:
The first  point of dissolution is slow release.  Later,  in the third 
point  of  dissolution  again  there is  fast  release.  So,  in  the  next  batch, 
added maize starch (0.85mg)  and sodium starch glycolate 5%.
Formulation - 6:
The release is increased as compare to the last batch. So, in the 
next batch removed the colloidal silicon dioxide  
Formulation - 7:
The release is decreased as compare to the last batch. 
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Formulation - 8:
In  this  batch,  the  release  of  ketorolac  tromethamine  was  better 
compare  to  the  last  batch.  This  formula  passes  the  every  aspect  of 
specifications
Formulation - 9:
In this batch, the release is decreased as compare to the last batch.
For stability:
Optimized batch were taken and subjected for stability, we 
observed on stability data, optimized batch passes the tests.
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9.1. CONCLUSION
The   Study  was  undertaken  with  an  aim  to  formulate,  develop  and 
evaluate  ketorolac  romethamine  different  excipients.  Preformualtion 
study was done initially  and results  directed for  the further  course  of 
formulation.  Based  on  preformulaion  studies  different  batches  of 
ketorolac were prepared using selected excipients.  Blend evaluated for 
tests loss on drying, bulk density, tapped density, compressibility index, 
Hausner  ratio  before  ring  punched  as  tablet.  Tablets  were  tested  for 
weight variation, thickness, hardness, friability and in vitro drug release 
as per official procedure. Change in dissolution parameter study made it 
suitable for minute physiological variables. 
 From the above results and discussion it is concluded that formulation 
ketorolac tromethamine containing 50% of micro crystalline cellulose, 
disintegrating agent Colloid silicon dioxide in Batch-VIII can be taken as 
an ideal or optimized formulation, it fulfills the requirements for short 
term release tablet and our study encourages for the further clinical trials 
and long term stability study on this formulation 
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